Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo Maps Pathways With Trial and Error


When Tatiana Nikolskaya says her company “is not doing what everyone else is doing,” she means it. GeneGo, incorporated in December 2000, is a genomics company that says the genome isn’t all it’s cracked up to be.

Nikolskaya, a former wetlab biologist originally from Russia, focuses on what she calls functional reconstruction. “We don’t care about actual sequence or structure,” says the president and CEO. “The only thing that is really important is function.” Basically, using biology and mathematical algorithms, GeneGo proposes pathways and then uses trial and error to test the theory. “If all the little parts fit together, it must be right,” Nikolskaya says.

According to GeneGo logic, trying to establish pathways and find drug targets by examining sequence and structure is useless at this point — “the human genome isn’t at that level yet,” she says. “The human genome sequence as it is would give us a skeleton. Not even a skeleton, maybe a tail and an ear.”

Sound a little too simple? It’s not, says Nikolskaya. “Building a [pathway] map is a very painful process.” If a proposed pathway is wrong — as is often the case — it will show itself, eventually. “At some point we’ll have a problem. And in chasing down the problem, we’ll find out what was wrong,” she explains.

Nikolskaya and her associates start with a model of the disease and rely heavily on ESTs to come up with potential pathways. She has worked on this problem for nearly three years. She recruited people for metabolic networking, computer support, and annotation; the company has so far identified more than 1,800 human-specific pathways.

Much of that comes from the mathematical expertise of Alexander Markov, one of GeneGo’s 13 employees. Markov is a Russian paleontologist who designed the architecture for the company’s highly flexible database. Roughly half the staff work in Moscow, focusing more on the math side, and half are scattered throughout the US, mainly working on the biological angle. “We’re a virtual company,” Nikolskaya says.

But she has found a place for the company to call home. Though the plans were to set up shop in Illinois, Michigan’s life sciences funding incentives proved too tempting, and Nikolskaya is looking at space in New Buffalo, a resort town on Lake Michigan. If functional reconstruction really does work so much better than sequence- and structure-based studies, perhaps she’s just preparing for an early retirement.

— Meredith Salisbury


The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.